Article
Oncology
Wei Ning, Pengkang Chang, Ji Zheng, Fan He
Summary: This case report highlights the potential effectiveness and safety of a second docetaxel rechallenge as a later-line treatment strategy for patients with mCRPC who are concerned about the high costs of multigene molecular testing and PARP inhibitors, as well as repeated prostate needle biopsy.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Dana M. Roque, Eric R. Siegel, Natalia Buza, Stefania Bellone, Dan-Arin Silasi, Gloria S. Huang, Vaagn Andikyan, Mitchell Clark, Masoud Azodi, Peter E. Schwartz, Gautam G. Rao, Jocelyn C. Reader, Pei Hui, Joan R. Tymon-Rosario, Justin Harold, Dennis Mauricio, Burak Zeybek, Gulden Menderes, Gary Altwerger, Elena Ratner, Alessandro D. Santin
Summary: This multi-center study evaluated the activity and safety of ixabepilone plus bevacizumab compared to ixabepilone alone in platinum-resistant/refractory ovarian cancer. The results showed that the combination of ixabepilone and bevacizumab had a higher overall response rate and longer progression-free survival, with good tolerability. Prior receipt of bevacizumab should not limit the use of ixabepilone plus bevacizumab in treatment.
BRITISH JOURNAL OF CANCER
(2022)
Review
Endocrinology & Metabolism
Camila Viecceli, Ana Carolina Viana Mattos, Vania Naomi Hirakata, Sheila Piccoli Garcia, Ticiana da Costa Rodrigues, Mauro Antonio Czepielewski
Summary: This meta-analysis concluded that ketoconazole can be considered a safe and efficacious option for Cushing's disease treatment after pituitary surgery.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Oncology
Judith Passildas-Jahanmohan, Jean-Christophe Eymard, Melanie Pouget, Fabrice Kwiatkowski, Isabelle Van Praagh, Laurent Savareux, Marc Atger, Xavier Durando, Catherine Abrial, Damien Richard, Angeline Ginzac Couve, Emilie Thivat, Brigitte Monange, Philippe Chollet, Hakim Mahammedi
Summary: Despite good compliance and verified absorption of curcumin, the study showed no significant difference in progression-free survival between the curcumin and placebo groups, as well as in the secondary endpoints such as PSA response rate, overall survival, and quality of life. Consequently, the study was discontinued due to lack of efficacy.
Article
Urology & Nephrology
Giulia Baciarello, Remy Delva, Gwenaelle Gravis, Youssef Tazi, Philippe Beuzeboc, Marine Gross-Goupil, Emmanuelle Bompas, Florence Joly, Charlotte Greilsamer, Thierry Nguyen Tan Hon, Philippe Barthelemy, Stephane Culine, Jean Francois Berdah, Mathilde Deblock, Raffaele Ratta, Aude Flechon, Caroline Cheneau, Aline Maillard, Geraldine Martineau, Isabelle Borget, Karim Fizazi
Summary: The preference for cabazitaxel over docetaxel among chemotherapy-naive men with mCRPC is mainly driven by reduced fatigue and improved quality of life.
Article
Urology & Nephrology
David Lorente, Casilda Llacer, Rebeca Lozano, Guillermo de Velasco, Nuria Romero-Laorden, Miguel Rodrigo, Angel Sanchez-Iglesias, Carlos di Capua, Elena Castro, Carlos Ferrer, Alfredo Sanchez-Hernandez, David Olmos
Summary: This study validated the prognostic value of the Armstrong risk model in patients treated with first-line androgen receptor signaling inhibitors, showing that low-risk patients received the greatest benefit. Further research is needed to establish the role of Armstrong risk groups for treatment selection in mCRPC patients.
Article
Oncology
Marit A. C. Vermunt, Merel van Nuland, Lisa T. van der Heijden, Hilde Rosing, Jos H. Beijnen, Andries M. Bergman
Summary: This study found no significant difference in the pharmacokinetics of docetaxel between patients with metastatic hormone-sensitive prostate cancer and metastatic castration-resistant prostate cancer. Therefore, differences in docetaxel pharmacokinetics cannot explain the differences in toxicity, and treatment adaptations are not recommended for the new population of patients with hormone-sensitive prostate cancer.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2022)
Article
Oncology
Olesya Vakhrusheva, Holger H. H. Erb, Vitus Braeunig, Sascha D. Markowitsch, Patricia Schupp, Patrick C. Baer, Kimberly Sue Slade, Anita Thomas, Igor Tsaur, Martin Puhr, Zoran Culig, Jindrich Cinatl, Martin Michaelis, Thomas Efferth, Axel Haferkamp, Eva Juengel
Summary: The therapeutic potential of artesunate (ART) on therapy-sensitive and docetaxel-resistant prostate cancer cells was investigated. The results showed that ART can inhibit the growth and proliferation of PCa cells, induce G0/G1 phase arrest, and promote cell apoptosis. Moreover, ART exhibited anticancer activity through different mechanisms in different PCa cell lines. Therefore, ART may have promise as a complementary treatment for advanced PCa.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Nanwei Xu, Jinge Zhao, Fengnian Zhao, Haoyang Liu, Wenlian Yin, Sha Zhu, Ling Nie, Guangxi Sun, Linmao Zheng, Zhenhua Liu, Diming Cai, Junru Chen, Jindong Dai, Yuchao Ni, Zhipeng Wang, Xingming Zhang, Jiayu Liang, Yuntian Chen, Xu Hu, Xiuyi Pan, Xiaoxue Yin, Xudong Zhu, Yaowen Zhang, Zilin Wang, Yuhao Zeng, Minghao Wang, Pengfei Shen, Ni Chen, Hao Zeng
Summary: This study aimed to explore the predictive value of neuroendocrine differentiation (NED) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone or docetaxel as first-line therapy. The results showed that NED was associated with shorter survival in both abiraterone and docetaxel treatment, suggesting that NED detection may help predict treatment outcomes and optimize treatment decisions for mCRPC patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Olayiwola O. Oduwole, Ariel Poliandri, Anthony Okolo, Phil Rawson, Milena Doroszko, Marcin Chrusciel, Nafis A. Rahman, Gilberto Serrano de Almeida, Charlotte L. Bevan, Wolfgang Koechling, Ilpo T. Huhtaniemi
Summary: The study suggests that FSH, rather than LH, may directly stimulate the growth of androgen-independent prostate cancer. Continuous suppression of FSH during GnRH antagonist treatment may offer a therapeutic advantage over agonist in inhibiting tumor growth.
Article
Oncology
Sascha D. Markowitsch, Kira M. Juetter, Patricia Schupp, Kristine Hauschulte, Olesya Vakhrusheva, Kimberly Sue Slade, Anita Thomas, Igor Tsaur, Jindrich Cinatl, Martin Michaelis, Thomas Efferth, Axel Haferkamp, Eva Juengel
Summary: Therapy resistance in advanced prostate carcinoma (PCa) leads to poor prognosis, necessitating new treatment options. Shikonin (SHI) has shown promising growth inhibition effects on both therapy-sensitive and DX-resistant PCa cell lines, primarily through induction of necroptosis.
Article
Urology & Nephrology
Ravi A. Madan, Fatima H. Karzai, Munjid Al Harthy, Daniel P. Petrylak, Joseph W. Kim, Philip M. Arlen, Inger Rosner, Marc R. Theoret, Lisa Cordes, Marijo Bilusic, Cody J. Peer, Nancy A. Dawson, Anna Couvillon, Amy Hankin, Moniquea Williams, Guin Chun, Helen Owens, Jennifer L. Marte, Min-Jung Lee, Yusuke Tomita, Akira Yuno, Jane B. Trepel, Sunmin Lee, Seth M. Steinberg, James L. Gulley, William D. Figg, William L. Dahut
Summary: The study evaluated the safety and efficacy of cabozantinib combined with docetaxel in mCRPC patients. Cabozantinib was found to be safely added to docetaxel treatment with potential enhanced efficacy. However, due to limited patient accrual, the phase 2 study was terminated early.
Article
Chemistry, Medicinal
Yujie Huang, You Zhai, Meijia Wu, Chengdong Chang, Jindan Luo, Dongsheng Hong, Qingwei Zhao, Yao Dai, Jian Liu
Summary: This study investigated the role of mTORC2 signaling in docetaxel-resistant prostate cells to find potential methods for clinical treatment. The expression of mTORC2 is crucial for docetaxel drug resistance in prostate cells. The mTORC1/2 inhibitor AZD8055 disrupts mTORC2 kinase activity more significantly than the mTORC1 inhibitor Rapamycin, leading to decreased docetaxel-mediated resistance. Therefore, reversing docetaxel resistance may become a therapeutic option for the treatment of metastatic castration-resistant prostate cancer patients.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Article
Biology
Kevin J. Tu, Sanjit K. Roy, Zachery Keepers, Manas R. Gartia, Hem D. Shukla, Nrusingh C. Biswal
Summary: The study investigates the effectiveness and molecular characteristics of the combination therapy of Docetaxel (DXL) and radiation in vitro. The results suggest that DXL sensitizes castration-resistant prostate cancer (CRPC) cells to radiation by downregulating CAV-1.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
(2023)
Article
Multidisciplinary Sciences
Jakob Haldrup, Simone Weiss, Linnea Schmidt, Karina Dalsgaard Sorensen
Summary: Enzalutamide, docetaxel, and cabazitaxel treatment resistance in mCRPC remains a challenge, and the genetic determinants are not well understood. By using CRISPR/Cas9 knockout screens, we identified several genes that modulate treatment response to these drugs, including BCL2L13, CEP135, E2F4, IP6K2, KDM6A, SMS, XPO4 for enzalutamide; DRG1, LMO7, NCOA2, ZNF268 for docetaxel; ARHGAP11B, DRG1, FKBP5, FRYL, PRKAB1, RP2, SMPD2, TCEA2, ZNF585B for cabazitaxel. Validation studies confirmed the impact of IP6K2, XPO4, DRG1, PRKAB1, and RP2 on treatment response. Individual validation of candidate hits from genome-wide CRISPR screens is crucial. The generalizability and translational potential of these findings need further investigation.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Evangelos Terpos, Michalis Liontos, Oraianthi Fiste, Flora Zagouri, Alexandros Briasoulis, Aimilia D. Sklirou, Christos Markellos, Efthymia Skafida, Alkistis Papatheodoridi, Angeliki Andrikopoulou, Konstantinos Koutsoukos, Maria Kaparelou, Vassiliki A. Iconomidou, Ioannis P. Trougakos, Meletios-Athanasios Dimopoulos
Summary: This study aimed to investigate the immunogenicity of different vaccines in cancer patients receiving immunotherapy. The results showed that a third booster dose significantly optimized antibody responses. The study highlights the importance of large cohort studies to evaluate vaccine effectiveness and durability of protection in the real-world setting.
Article
Oncology
Aristotelis Bamias, Axel Merseburger, Yohann Loriot, Nicholas James, Ernest Choy, Daniel Castellano, F. Lopez-Rios, Fabio Calabro, Mario Kramer, Guillermo de Velasco, Roubini Zakopoulou, Kimon Tzannis, Cora N. Sternberg
Summary: An improved prognostic model was developed for patients with advanced urothelial cancer receiving second-line atezolizumab. This model provides better prediction of overall survival compared to the traditional Bellmunt Risk Score algorithm and can assist in guiding the selection of patients for second-line immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Vasiliki Gkalea, Despina Fotiou, Meletios Athanasios Dimopoulos, Efstathios Kastritis
Summary: It is increasingly recognized that patients with monoclonal gammopathy (MG) who do not meet criteria for malignant disease and treatment initiation may have other manifestations that are clinically significant and could provide a rationale for treatment. These patients are at higher risk for thrombosis, including venous, arterial, and micro-thrombotic events. The challenge is to identify high-risk MG patients for thrombotic events and apply appropriate preventive measures.
Article
Oncology
Dimitra Rafailia Bakaloudi, Rafee Talukder, Genevieve Ihsiu Lin, Dimitrios Makrakis, Leonidas N. Diamantopoulos, Nishita Tripathi, Neeraj Agarwal, Roubini Zakopoulou, Aristotelis Bamias, Jason R. Brown, David J. Pinato, James Korolewicz, Tanya Jindal, Vadim S. Koshkin, Jure Murgic, Marija Miletic, Ana Frobe, Jeffrey Johnson, Yousef Zakharia, Alexandra Drakaki, Alejo Rodriguez-Vida, Macarena Rey-Cardenas, Daniel Castellano, Lucia Alonso Buznego, Ignacio Duran, Clara Castro Carballeira, Rafael Morales Barrera, David Marmorejo, Rana R. McKay, Tyler Stewart, Shilpa Gupta, Andrew Thomas Ruplin, Evan Y. Yu, Ali R. Khaki, Petros Grivas
Summary: This study retrospectively observed the clinical features and outcomes of aUC patients receiving avelumab maintenance treatment. The results showed that prior response to platinum-based chemotherapy, ECOG PS 0, and absence of liver metastases were favorable prognostic factors.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Medicine, General & Internal
Ioannis Rodolakis, Vasilios Pergialiotis, Michalis Liontos, Dimitrios Haidopoulos, Dimitrios Loutradis, Alexandros Rodolakis, Aristotelis Bamias, Nikolaos Thomakos
Summary: The chemotherapy response score is a predictive index for survival outcomes in advanced-stage epithelial ovarian cancer patients undergoing interval debulking surgery. However, its accuracy in determining patients with a shorter overall survival is still debated and there is a need for standardization of the scoring system. Research should also focus on the predictive value of determining patients with platinum resistance to identify those at risk of recurrence. This review provides a summary of current knowledge and suggests directions for future research.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Vassiliki Spiliopoulou, Efstathios Kastritis, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Maria Gavriatopoulou
Summary: This study assessed the effectiveness and tolerability of belantamab mafodotin in triple-class refractory patients with multiple myeloma. It showed promising results in some patients and had manageable toxicity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Nutrition & Dietetics
Melpomeni Peppa, Aspasia Manta, Ioanna Mavroeidi, Constantinos Nastos, Emmanouil Pikoulis, Konstantinos Syrigos, Aristotelis Bamias
Summary: Hormone-related cancers are dependent on hormone levels that play an essential role in cancer growth. Diet, along with traditional risk factors, seems to be an important environmental factor that explains the increased prevalence of these cancers. Carbohydrates, specifically glycemic index and glycemic load, are implicated as risk factors for hormone-related cancers by affecting insulin metabolism and inducing inflammation and oxidative stress. This article reviews existing data on the impact of diets focusing on glycemic index and glycemic load estimates on hormone-related cancers.
Article
Oncology
Angeliki Andrikopoulou, Charalampos Theofanakis, Christos Markellos, Maria Kaparelou, Konstantinos Koutsoukos, Kleoniki Apostolidou, Nikolaos Thomakos, Dimitrios Haidopoulos, Alexandros Rodolakis, Meletios-Athanasios Dimopoulos, Flora Zagouri, Michalis Liontos
Summary: The optimal time interval between neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) in high-grade serous ovarian carcinoma (HGSC) is unclear. A retrospective study was conducted on HGSC patients who underwent NACT followed by IDS in a 15-year period. The study found that performing IDS within four weeks after NACT was associated with better survival outcomes. Multivariate analysis showed that a short time interval (<4 weeks) from NACT to IDS was an independent factor of both PFS and OS.
Article
Oncology
Lisa B. Leypoldt, Maria Gavriatopoulou, Britta Besemer, Hans Salwender, Marc S. Raab, Axel Nogai, Cyrus Khandanpour, Volker Runde, Anna Jauch, Manola Zago, Peter Martus, Hartmut Goldschmidt, Carsten Bokemeyer, Meletios A. Dimopoulos, Katja C. Weisel
Summary: This study evaluated the safety and efficacy of daratumumab, bortezomib, and dexamethasone in multiple myeloma patients with severe renal function impairment. The treatment showed an overall response rate of 67% and improved renal function in patients. This study suggests that this treatment regimen could be considered in the clinical practice for multiple myeloma patients with severe renal function impairment.
Review
Oncology
Ioanna E. Stergiou, Stavros P. Papadakos, Anna Karyda, Ourania E. Tsitsilonis, Meletios-Athanasios Dimopoulos, Stamatios Theocharis
Summary: The EPH/ephrin signaling axis plays a crucial role in both embryonic development and adult life, and recent studies have shown its involvement in the pathogenesis of various types of solid tumors. In normal hematopoiesis, different patterns of EPH/ephrin expression are associated with the maintenance, differentiation, and function of hematopoietic stem cells and their mature offspring. Abnormalities in the EPH/ephrin pathway have been found to contribute to the development of hematologic malignancies, with both tumor-promoting and tumor-suppressive effects. Understanding the complexity of this signaling pathway in normal and malignant hematopoiesis is essential for the development of potential therapeutic targets.
Review
Urology & Nephrology
Aristotelis Bamias, Arnulf Stenzl, Flora Zagouri, Angeliki Andrikopoulou, Peter Hoskin
Summary: Unlike other cancers, there is a lack of systematic investigation on oligometastatic disease (OMD) in bladder cancer (BC). This article aims to assist in developing a definition of oligometastatic BC (OMBC) and providing recommendations on staging and local therapies through a systematic review.
EUROPEAN UROLOGY OPEN SCIENCE
(2023)
Review
Medicine, General & Internal
Efstathia Liatsou, Ioanna Tatouli, Andreas Mpozikas, Maria-Markella Pavlou, Hariklia Gakiopoulou, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Sofoklis Kontogiannis, Meletios Athanasios Dimopoulos
Summary: Tenofovir disoproxil fumarate (TDF) is a drug used to treat patients with HIV and HBV infections, but it may cause acute renal failure and Fanconi syndrome in a few cases. The risk of renal toxicity in HBV patients appears to be low, but kidney function should still be monitored.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Oncology
Alexander Georgakopoulos, Aristotle Bamias, Sophia Chatziioannou
Summary: PSMA PET/CT has emerged as a promising diagnostic imaging tool for the diagnosis and management of PC. It improves the detection of clinically significant PC and is more accurate than CT and bone scan in the initial staging.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Ioanna Barla, Panagiotis Efentakis, Sofia Lamprou, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Evangelos Terpos, Ioanna Andreadou, Nikolaos Thomaidis, Evangelos Gikas
Summary: The antineoplastic agent carfilzomib (Cfz) is used to treat multiple myeloma; however, it can cause cardiotoxicity and nephrotoxicity as common adverse effects. While the mechanisms of these side effects are well-established, there is limited research on the drug's metabolic alterations and their impacts.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, Research & Experimental
Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, Panagiotis Malandrakis, Evangelos Eleutherakis-Papaiakovou, Vassiliki Spiliopoulou, Rodanthi-Eleni Syrigou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Maria Roussou, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Evangelos Terpos
Summary: Tixagevimab/cilgavimab (Evusheld) appears to be beneficial for high-risk immunocompromised patients with multiple myeloma in preventing COVID-19. Administration of the drug resulted in increased neutralizing-antibody levels and a low incidence of COVID-19, with no new safety concerns emerging.
